Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
467 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03763604 | Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 14 | Dec 16, 2024 | clinicaltrials |
| NCT02588261 | A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations(SOLAR) | terminated | Phase 3 | 530 | Astellas Pharma Global Development, Inc.INDUSTRY |
| 23 |
| Dec 10, 2024 |
| clinicaltrials |
| NCT03035032 | A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients | completed | Phase 4 | 107 | Astellas Pharma Singapore Pte. Ltd.INDUSTRY | 8 | Nov 26, 2024 | clinicaltrials |
| NCT03944798 | Surveillance AFter Extremity Tumor surgerY(SAFETY) | active not recruiting | N/A | 310 | McMaster UniversityOTHER | 14 | Nov 22, 2024 | clinicaltrials |
| NCT06698484 | To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)(CAR-T for NHL) | recruiting | Phase 2 | 20 | National University of MalaysiaOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06293508 | mHealth Behavioural Intervention to Increase Breast Cancer Screening Rates Among Members of the Public(mBLISS-B) | terminated | N/A | 1,180 | Clinical Research Centre, MalaysiaOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06684067 | Effect of Patient Navigation on Colonoscopy Completion Screening Rate for Colorectal Cancer. | completed | N/A | 52 | University of MalayaOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT03013504 | A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients(TROIKA) | completed | Phase 3 | 503 | Prestige Biopharma LimitedINDUSTRY | 13 | Nov 6, 2024 | clinicaltrials |
| NCT03239340 | A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib(ELIOS) | completed | Phase 2 | 154 | AstraZenecaINDUSTRY | 5 | Oct 21, 2024 | clinicaltrials |
| NCT03189719 | First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590) | completed | Phase 3 | 749 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Oct 15, 2024 | clinicaltrials |
| NCT05286619 | A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)(PIPER) | recruiting | Phase 2 | 63 | University of MalayaOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03447769 | Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A(Canopy-A) | terminated | Phase 3 | 1,382 | Novartis PharmaceuticalsINDUSTRY | 41 | Oct 9, 2024 | clinicaltrials |
| NCT03839823 | Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer(RIGHT Choice) | completed | Phase 2 | 222 | Novartis PharmaceuticalsINDUSTRY | 13 | Oct 9, 2024 | clinicaltrials |
| NCT04139317 | Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% | terminated | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 16 | Oct 9, 2024 | clinicaltrials |
| NCT04899349 | Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant(EPIK-B4) | terminated | Phase 2 | 2 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 9, 2024 | clinicaltrials |
| NCT01794793 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | completed | Phase 4 | 337 | RECORDATI GROUPINDUSTRY | 28 | Oct 1, 2024 | clinicaltrials |
| NCT05099978 | Asian Multicenter Prospective Study of ctDNA Sequencing(A-TRAIN) | unknown | — | 506 | National Cancer Center, JapanOTHER_GOV | 8 | Sep 4, 2024 | clinicaltrials |
| NCT06566937 | The Effectiveness of E-health Intervention in Improving Mental Health Outcomes Among Breast Cancer Patients | recruiting | N/A | 114 | National University of MalaysiaOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT02112656 | Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)(OPTIMA) | completed | Phase 3 | 554 | ImunonINDUSTRY | 14 | Aug 20, 2024 | clinicaltrials |
| NCT06504927 | Biomarker Discovery in Lung Cancer - Malaysia | recruiting | — | 400 | University of MalayaOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT03719690 | Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy(AIM-HN/SEQ-HN) | completed | Phase 2 | 296 | Kura Oncology, Inc.INDUSTRY | 16 | Jun 21, 2024 | clinicaltrials |
| NCT05316064 | Reducing Abundance of Human Papilloma Virus in Women by Taking Probiotic | withdrawn | Phase 2 / Phase 3 | 0 | Universiti Sains MalaysiaOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT00617981 | Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC) | completed | Phase 3 | 701 | ImunonINDUSTRY | 11 | May 3, 2024 | clinicaltrials |
| NCT03217812 | A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) | completed | Phase 3 | 220 | Janssen Research & Development, LLCINDUSTRY | 5 | Apr 25, 2024 | clinicaltrials |
| NCT03837327 | Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy(VOCAL) | completed | — | 1,025 | Venn Biosciences CorporationINDUSTRY | 4 | Apr 23, 2024 | clinicaltrials |
| NCT06336395 | Ma-Spore ALL 2020 Study | recruiting | Phase 2 | 500 | National University Hospital, SingaporeOTHER | 2 | Mar 28, 2024 | clinicaltrials |
| NCT05217407 | Marker Assisted Selective ThErapy in Rare Cancers: Knowledge Database Establishing registrY Asia(MASTERKEY ASIA) | recruiting | — | 1,000 | National Cancer Center, JapanOTHER_GOV | 7 | Mar 22, 2024 | clinicaltrials |
| NCT04767802 | PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit(PACIFIC) | completed | Phase 2 | 20 | Protagonist Therapeutics, Inc.INDUSTRY | 2 | Mar 18, 2024 | clinicaltrials |
| NCT02278120 | Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer(MONALEESA-7) | completed | Phase 3 | 672 | Novartis PharmaceuticalsINDUSTRY | 30 | Mar 12, 2024 | clinicaltrials |
| NCT01120184 | A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) | completed | Phase 3 | 1,095 | Hoffmann-La RocheINDUSTRY | 38 | Mar 4, 2024 | clinicaltrials |
| NCT06250166 | Feasibility, Acceptability, and Effectiveness of an Individualized Plant-based (iPLANT) Diet Plan in Colorectal Cancer: Mixed Method Embedded Design | unknown | N/A | 92 | National Cancer Institute, MalaysiaOTHER_GOV | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04964908 | Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia(CREEK) | completed | — | 1,088 | AstraZenecaINDUSTRY | 17 | Feb 20, 2024 | clinicaltrials |
| NCT00565708 | Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers(ASCOLT) | unknown | Phase 3 | 1,587 | National Cancer Centre, SingaporeOTHER | 10 | Feb 2, 2024 | clinicaltrials |
| NCT06238583 | Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors | no longer available | — | — | BayerINDUSTRY | 11 | Feb 2, 2024 | clinicaltrials |
| NCT03225586 | Prospective Urban Rural Epidemiology Study(PURE) | recruiting | — | 200,000 | Population Health Research InstituteOTHER | 25 | Jan 31, 2024 | clinicaltrials |
| NCT05955157 | Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma | unknown | Phase 2 / Phase 3 | 52 | University of MalayaOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT00957086 | Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer | unknown | Phase 3 | 710 | National Cancer Centre, SingaporeOTHER | 13 | Jan 9, 2024 | clinicaltrials |
| NCT03871816 | A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer | completed | — | 14,532 | Janssen Research & Development, LLCINDUSTRY | 25 | Dec 11, 2023 | clinicaltrials |
| NCT00355238 | A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer | completed | Phase 2 | 137 | Bristol-Myers SquibbINDUSTRY | 8 | Dec 1, 2023 | clinicaltrials |
| NCT02422615 | Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-3) | completed | Phase 3 | 726 | Novartis PharmaceuticalsINDUSTRY | 30 | Nov 30, 2023 | clinicaltrials |
| NCT04834167 | OneDoc Picopulse™ for the Treatment of Melasma Among Malaysian Women | completed | N/A | 32 | Universiti Tunku Abdul RahmanOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT06128798 | Effect of Preoperative Immunonutrition Versus Standard Oral Nutrition in Patient Undergoing Colorectal Surgery. | unknown | N/A | 58 | Hospital Universiti Sains MalaysiaOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT02941926 | Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC(COMPLEEMENT-1) | completed | Phase 3 | 3,246 | Novartis PharmaceuticalsINDUSTRY | 38 | Oct 24, 2023 | clinicaltrials |
| NCT06064331 | Effect of Intravenous Lignocaine Infusion on Intraoperative End Tidal Desflurane Concentration Requirements | completed | N/A | 48 | Universiti Kebangsaan Malaysia Medical CentreOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT03761225 | Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer | completed | Phase 3 | 714 | AB ScienceINDUSTRY | 6 | Sep 29, 2023 | clinicaltrials |
| NCT05935696 | A Prospective Observational Study on the Role of Transthoracic Ultrasound in Differentiating Tuberculous From Malignant Pleural Effusion(TUS-TBE) | unknown | — | 100 | Sarawak General HospitalOTHER | 1 | Jul 7, 2023 | clinicaltrials |
| NCT02578641 | A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients(VANCE) | completed | Phase 3 | 330 | Tessa TherapeuticsINDUSTRY | 5 | Jun 28, 2023 | clinicaltrials |
| NCT01104155 | Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 123 | Eisai Inc.INDUSTRY | 7 | Jun 22, 2023 | clinicaltrials |
| NCT05910541 | The Efficacy of Multisession Mindful Breathing in Symptom Reduction Among Patients With Advanced Cancers | completed | N/A | 80 | University Malaysia SarawakOTHER | 1 | Jun 18, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials